This study investigates the pharmacokinetic profile and safety of an investigational medication in patients with advanced solid tumors or blood-related cancers. The purpose is to understand how the body absorbs, breaks down, and eliminates the medication, particularly in patients with varying levels of liver function, including normal, mild, moderate, or severe impairment.
Participants will receive the investigational medication once a week for six weeks in a seven-week cycle. The study is open-label and non-randomized, meaning all participants will know what treatment they are receiving, and they will not be randomly assigned to different study arms.
- Who can participate: Adults aged 18 and older with advanced solid tumors or hematological malignancies and normal to severely impaired liver function may participate. Key eligibility includes adequate blood and kidney function and an ECOG performance status of 0-2.
- Study details: Participants will take the investigational medication weekly and adhere to study requirements, including using two forms of contraception if applicable. The study will monitor the medication's effects on the body and gather safety data.
How understandable was the trial content above?
Hard to understand
Easy to understand